Magnesium sulphate and other anticonvulsants for women with pre. The magpie trial, a randomised trial comparing magnesium sulphate with placebo for preeclampsia. The use of magnesium sulphate for the treatment of severe pre. The aim of this study was to assess longterm effects for women following the use of magnesium sulphate for preeclampsia. The neuroprotective effect of antenatal magnesium sulfate on very preterm infants has been demonstrated in goodquality randomised controlled trials and metaanalyses. Pain associated with intramuscular injections and the need for an electronic infusion pump for use intravenously represent significant barriers to broader utilization. Magnesium administered prior to preterm delivery crosses over to the foetal circulation and acts via several pathways to reduce perinatal neuronal damage. Oct 26, 2002 the results of the magpie trial june 1, p 18771 confirm claims that magnesium sulphate given during labour and for at least 24 h post partum will reduce the risk of seizures in women with severe preeclampsia or imminent eclampsia. Do women with preeclampsia, and their babies, benefit from. A recent large randomized trial suggests that the gestational age of the infant may be critical in determining whether antenatal magnesium sulfate is beneficial.
Costeffectiveness of prophylactic magnesium sulphate for 9996 women with preeclampsia from 33 countries. Magnesium sulphate significantly decreases the risk of eclampsia in pregnant women with preeclampsia. A randomized trial comparing the pharmacology of magnesium. A randomized controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe preeclampsia.
Magnesium sulphate given as neuroprotection to women at risk of preterm birth before 30 weeks of gestation has been evaluated in one previous trial. Magnesium sulphate for fetal neuroprotection sciencedirect. Magnesium sulphate more than halved the risk of eclampsia, and probably reduced the risk of maternal death. Pdf do women with preeclampsia, and their babies, benefit. The use of magnesium sulphate for the treatment of severe. A randomized, controlled trial of magnesium sulfate for. Do women with preeclampsia, and their babies, benefit from magnesium sulphate. Magnesium sulphate for eclampsia or eclampsia prophylaxis. Doyle lw, crowther ca, middleton p, marret s, rouse d. Magnesium sulfate an overview sciencedirect topics.
Magnesium sulphate neuroprotection of preterm infants uncontrolled document when printed published. Pdf on jan 1, 2002, the magpie trial collaborative group and others published do women with preeclampsia, and their babies, benefit from magnesium sulphate. Mgso 4 is also superior to placebo and nimodipine for prevention of eclampsia in women diagnosed with preeclampsia. Do women with preeclampsia, and their babies, benefit. Nhs economic evaluation database nhs eed 31 december 2006. Severe preeclampsia is a common cause of maternal death, leading to approximately 50,000 maternal deaths per year. In the magnesium sulphate for prevention of eclampsia magpie trial, researchers randomized women with preeclampsia in labor to receive magnesium sulfate or placebo and assessed rates of eclampsia. Preeclampsia is a systemic disorder affecting 28% of pregnancies. Prior to the magpie trial, anticonvulsants had been used for many years to prevent the risk of seizure, with magnesium sulphate emerging as possibly the most. Magnesium sulfate for neuroprotection should only be given if preterm birth is likely within the next 24 hours. Single loading dose of magnesium sulphate in severe. Between 1998 and 2001, 10 141 women were recruited to the magpie trial at 175 hospitals in 33 countries.
Magpie trial, which involved 10141 women with preeclampsia and their carers in 175 hospitals in 33 countries, shows that magnesium sulphate reduces the risks of eclampsia among women with preeclampsia. Dec 12, 2006 magnesium sulphate given as neuroprotection to women at risk of preterm birth before 30 weeks of gestation has been evaluated in one previous trial. Magnesium sulphate is the anticonvulsant of choice for women with eclampsia. The magpie trial is an international randomised trial comparing magnesium sulphate with placebo for women with preeclampsia. Magnesium sulphate neuroprotection of preterm infants. Who recommendation on the use of magnesium sulfate for. Oct 26, 2002 women diagnosed with preeclampsia were excluded from the magnet trial to avoid confounding. Overall, 9024 children were included in the analysis of outcome at discharge from hospital. We hypothesize that an alternative regimen based on serial intravenous iv boluses can produce. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. In the magnesium sulphate for prevention of eclampsia magpie trial, researchers randomized women with preeclampsia in labor to receive.
Magnesium sulfate mgso 4, the preferred pharmacological intervention for treatment of eclamptic seizures, has been shown to have greater efficacy and fewer complications than treatment with diazepam or phenytoin. Magnesium sulphate given before verypreterm birth to protect infant brain. In the magpie trial and the earlier eclampsia trial, maternal mortality was reduced but failed to reach statistical significance. The results of the magpie trial june 1, p 18771 confirm claims that magnesium sulphate given during labour and for at least 24 h post partum will reduce the risk of seizures in women with severe preeclampsia or imminent eclampsia. Judicious use of magnesium sulfate for eclampsia mdedge obgyn. Loading dose of magnesium sulphate versus standard regime for. Magnesium sulphate prevented eclampsia in women with pre. This hospital, like many others in this country and around the world, is involved in a study to try and find out if.
Like the evidence generated by the collaborative eclampsia trial, the evidence from the magpie trial is. Primary outcomes are eclampsia and death of the baby. Who recommendation on the use of magnesium sulfate for fetal. Metaanalysis of the trial data indicates that antenatal magnesium.
The trial is coordinated from oxford, and in the uk women are entered into the study by telephoning a randomisation service. The magpie trial magnesium sulphate mgso 4 was first introduced to control convulsions in 1925, but it was the collaborative eclampsia trial in 1995 that confirmed the efficacy of mgso 4 in the treatment of severe preeclampsia and eclampsia. Altman d, carroli g, duley l, farrell b, moodley j, neilson j, et al. This trial tests whether magnesium sulfate given to a woman in labor with a premature fetus 24 to 31 weeks out of 40 will reduce the rate of death or moderate to severe cp in the children at 2 years. Nov 17, 2015 magnesium sulfate for neuroprotection should only be given if preterm birth is likely within the next 24 hours. There did not appear to be any substantive harmful. Australian injectable drugs handbook, 6th edition, society of hospital pharmacists of australia 2014.
Nevertheless, the unexpected paediatric complications in our tocolytic magnesium trial led us to scrutinise the magpie data set, enquiring about possible adverse paediatric effects when magnesium sulphate was used instead for the prevention of eclampsia. The magpie trial showed that it is also effective for preventing. Uk medical research council, department for international. Beneficial effects of antenatal magnesium sulfate beam trial. The trial also called magpie trial was a randomized, placebo. The magpie trial is comparing magnesium sulphate with placebo for treatment of women with preeclampsia. Magnesium sulphate for neuroprotection in preterm births magnesium sulphate for neuroprotection in preterm births trial of magnesium sulphate for the prevention of cerebral palsy. Primary measures of outcome are eclampsia and death of the baby. The median time from 35 magnesium sulfate administration to birth was reported in only two of the trials that generated the evidence 1 hour 38 minutes and 3. Between 1998 and 2001, 8804 women with preeclampsia during pregnancy or labour were recruited to the magpie trial at 175 hospitals in 33 countries.
However, the gdg felt that administering magnesium sulfate at any. The magpie trial showed that magnesium sulphate was effective regardless of severity of preeclampsia, gestational age at trial entry, or whether delivery had occurred. The magpie trial compared magnesium sulphate with placebo for women with preeclampsia. Magnesium sulphate for neuroprotection in preterm births mar 01, 2007 methods. A randomized, controlled trial of magnesium sulfate for the. In this multicenter, placebocontrolled, randomized trial of intravenous magnesium sulfate in women at imminent risk for delivery between 24 and 31 weeks of gestation, magnesium sulfate did not sig. Like the evidence generated by the collaborative eclampsia. Outcome for women at 2 years magpie trial followup study collaborative group. Findings demonstrate that magnesium sulfate meaningfully reduces the risk of eclamptic seizures among women with preeclampsia. Assessment at 23 years after delivery for women recruited to the magpie trial recruitment in 19982001, isrctn 86938761, which compared magnesium sulphate with placebo for preeclampsia. Women diagnosed with preeclampsia were excluded from the magnet trial to avoid confounding. This hospital, like many others in this country and around the world, is involved in a study to try and find out if magnesium sulphate is helpful for women. Magnesium sulphate for neuroprotection in preterm births.
1104 1232 304 1293 801 1463 1518 481 297 1358 1401 268 137 707 1133 285 618 1405 1329 1229 412 749 38 490 301 814 1200 988 1217 1357 698 1376 396 1335 537 1158 556 92 120 341 1448 172